Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
- 31 July 2006
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (7) , 888-893
- https://doi.org/10.1016/j.cgh.2006.04.022
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The complicated path to true causes of disease: role of nuclear factor B in inflammatory bowel diseaseGut, 2005
- Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanerceptAlimentary Pharmacology & Therapeutics, 2005
- Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s diseaseGastroenterology, 2003
- Effects of infliximab on apoptosis and reverse signaling of monocytesGastroenterology, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot studyAlimentary Pharmacology & Therapeutics, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Role of Cytokines in the Pathogenesis of Inflammatory Bowel DiseaseAnnual Review of Medicine, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997